scout
Opinion|Videos|December 6, 2023

The NRG-GY018 Trial: Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer

Dr Thomas C. Krivak highlights key data from the GY018 trial investigating chemotherapy plus pembrolizumab in both dMMR and pMMR advanced endometrial cancer, confirming and extending the findings from the RUBY trial supporting pembrolizumab's approval and use in both dMMR and pMMR populations.

Episodes in this series

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME